SAN DIEGO, July 17, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial … […]
Multi-Site Study to Track Improvements to Safety and Results Achieved through Process Automation for the Preservation of Embryos and Other Fertility Cells
NEW YORK and CHICAGO and SAN DIEGO, July 16, 2019 /PRNewswire/ — TMRW, the creator of the firs… […]
SAN DIEGO, July 16, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, toda… […]
SAN DIEGO, July 15, 2019 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company wil… […]
— Further Extends Cibus Intellectual Property for its Precise Gene-Editing Technologies —
SAN DIEGO, July 15, 2019 /PRNewswire/ — Cibus, a leader in advanced plant-breeding technologies, today announced it has been granted a new patent related to … […]
Management team to meet with investment institutions, analysts and shareholders in NYC to provide an overview of the Company and its advancing clinical development of onvansertib
SAN DIEGO, July 15, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV)… […]
– FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa- Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 26, 2020- New D… […]
SAN DIEGO, July 9, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati’s investiga… […]
Facility to lead discovery of new preclinical applications, disease modeling techniques, and drug discovery opportunities utilizing StemoniX’s proprietary microOrgan® platforms
LA JOLLA, Calif., July 8, 2019 /PRNewswire/ — StemoniX, a biotech compan… […]
SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.The smaller delivery volume enables use of established drug container and device technology developed f… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
